Press Releases

Clene to Present at Upcoming Investor Conferences
SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5 th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners Investor Conference Fall Event and host 1x1 investor meetings at both conferences.
September 22, 2026
PDF Version
Clene Announces $4 Million Registered Direct Offering
Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders $4 million registered direct offering priced at market under Nasdaq rules Proceeds are expected to be sufficient to
September 15, 2026
PDF Version
Clene to Present at Upcoming September Investor Conferences
SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference and host 1x1 investor meetings at both conferences.
September 3, 2026
PDF Version
Clene to Present at the Emerging Growth Conference
SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the Emerging Growth Conference. Virtual Presentation Details Date: August 19, 2026 Time of Presentation: 3:10 p.m. ET Format: Corporate update A webcast of the presentation
August 17, 2026
PDF Version
Clene to Present at The Canaccord 46th Annual Growth Conference
SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases,
July 29, 2026
PDF Version
Clene Announces $7 Million Underwritten Offering of Common Stock
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative
May 5, 2026
PDF Version
Displaying 1 - 10 of 18